Leadership With Decades of Oncology Experience

Dr. Goldberger holds a Ph.D. in cancer immunotherapy from the Weizmann Institute of Science and was post-doctoral fellow at Stanford University where he conducted research in systems immunology. He brings more than 10 years of experience in corporate development and business operations in the biotech and life science tools verticals where he held key positions at Instil Bio (NASDAQ:TIL), ImmPACT Bio (acquired by Lyell Immunopharma, NASDAQ:LYELL) and Standard Biotools (NASDAQ:LAB).

Dr. Ari VanderWalde is a medical oncologist with >15 years experience in drug development, academic oncology, and clinical trials. Following residency in internal medicine at UCLA and fellowship in Hematology/Oncology at City of Hope, Dr. VanderWalde served as the US Medical Lead on talimogene laherparepvec, an oncolytic therapy that obtained FDA and EMA approval in the treatment of melanoma. He has been the Vice Chair of the Precision Oncology Alliance as well as the Global Chair of Clinical Trials at Caris Life Sciences since 2021. An internationally recognized cancer researcher, Dr. VanderWalde was previously the Director of Research at West Cancer Center and Research Institute in Memphis, TN, where he is still a member of the research faculty. He held a dual appointment with the University of Tennessee Health Science Center as Associate Vice Chancellor of Clinical Research and Associate Professor in Hematology/Oncology. His primary research has been in melanoma, immunotherapy and targeted therapy including combinations of therapy and mechanisms of resistance.

Dr. Laura Millichamp qualified as a Pharmacist, before completing a PhD in the field of topical products. She was a Pharmaceutical Assessor at the MHRA for over 7 years, where she assessed Marketing Authorization Applications and Scientific Advice requests submitted through National and European procedures. Laura then moved into Consulting supporting companies at all stages of product development with strategic and technical advice relating to activities including IND/IMPD data generation and authoring, early access initiatives (PRIME/ODD applications), Scientific Advice procedures, Marketing Authorization Applications and Lifecycle Maintenance.

As a board certified toxicologist, Ms. Johnson has been assisting pharmaceutical companies with all phases of nonclinical development for more than 20 years. Activities include representing clients at FDA, negotiating nonclinical testing strategies, preparing INDs, NDAs, briefing documents, and monitoring studies. Prior to that she worked in agricultural and industrial chemical product registrations with EPA and litigation support work.